Expression of CD4+CD25+ regulatory T cells in aged patients with acute myeloid leukemia

doi:10.3969/j.issn.2095-4344.2015.01.027

Abstract

Abstract:

BACKGROUND: High expression of CD4⁺CD25⁺ regulatory T cells is proved to exist in many patients with malignant tumors in vivo. Recent studies have found that CD4⁺CD25⁺ regulatory T cells also show a high percentage of expression in the peripheral blood of patients with acute myeloid leukemia.
OBJECTIVE: To analyze the characteristics of expression of CD4⁺CD25⁺ regulatory T cells in aged patients with acute myeloid leukemia.
METHODS: Ninety-two patients with newly diagnosed acute myeloid leukemia were enrolled and divided into middle-young age group (< 60 years old, n=22) and aged observation group (> 60 years old, n=70). Thirty-two patients in the aged observation group underwent standardized chemotherapy and showed complete remission, who acted as complete remission group; and the remaining 38 patients acted as aged group, including 6 cases of M2, 19 cases of M3, 7 cases of M4, and 6 cases of M5 according to FAB classification. At the same period, another 42 healthy persons for hospital examination were selected as control group. Peripheral blood samples were extracted to detect the expression of CD4⁺CD25⁺ regulatory T cells.
RESULTS AND CONCLUSION: The proportions of CD4⁺CD25^high FOXP3⁺ Treg cells and CD4⁺FOXP3⁺ T cells in the aged and complete remission groups were higher than those in the control group (P < 0.01), and moreover, these two proportions were higher in the aged group than the complete remission group (P < 0.01). The proportions of CD4⁺CD25^high FOXP3⁺ Treg cells and CD4⁺FOXP3⁺ T cells in the aged group were higher than those in the middle-young age group (P < 0.01). There were no difference in the proportions of CD4⁺CD25^high FOXP3⁺ Treg cells and CD4⁺ FOXP3⁺T cells among different subgroups of the aged group (P > 0.05). The proportion of CD4⁺CD25^high FOXP3⁺Treg cells in the peripheral blood was positively related to the proportion of CD4⁺FOXP3⁺ T cells in aged patients with acute myeloid leukemia (r=0.87, P=0.019). The proportion of CD4⁺CD25⁺ Treg cells in the aged patients with newly diagnosed acute myeloid leukemia is higher than that in healthy individuals and young patients with acute myeloid leukemia.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: Leukemia, Myeloid, Acute, Aged, Leukemia, T-Cell

CLC Number:

R394.2

Bo Li-kui. Expression of CD4⁺CD25⁺ regulatory T cells in aged patients with acute myeloid leukemia[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(1): 151-155.

Figures/Tables 3

References

[1] Rooney CM.Can Treg elimination enhance NK cell therapy for AML? Blood. 2014;123(25):3848-3849.
[2] 崔俊杰.脐带间充质干细胞对阿糖胞苷诱导的HL-60细胞凋亡影响的研究[D].北京协和医学院中国医学科学院,2013.
[3] 周华,周倩兰,唐晓文,等. allo-HSCT治疗进展期难治性急性髓系白血病的长期随访结果[J].浙江临床医学,2014,16(7): 1017- 1018, 1021.
[4] 刘会兰,孙自敏,杨会志,等.自体外周血干细胞移植治疗急性髓细胞白血病[J].临床输血与检验,2007,9(4):313-315.
[5] Sriskanthadevan S,Jeyaraju DV,Chung TE,et al.AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress.Blood. 2015 Jan 28. pii: blood-2014-08-594408. [Epub ahead of print]
[6] Govindaraj C, Madondo M,Kong YY,et al.Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.Am J Hematol.2014;89(8):795-802.
[7] Govindaraj C,Tan P,Walker P,et al.Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.Clin Cancer Res.2014;20(3): 724-735.
[8] Zhou Q,Hu Y,Howard OM,et al.In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.Cytokine. 2014; 65(1):56-64.
[9] Goodyear OC,Dennis M,Jilani NY,et al.Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).Blood.2012;119(14):3361-3369.
[10] 杜晓辉,刘利利,宁宁,等.胃癌患者血清调节性T细胞、细胞毒性T淋巴细胞的检测及意义[J].中华实验外科杂志,2013,30(12): 2704-2706.
[11] 李晶晶,牛倩,唐笛娇,等.多发性骨髓瘤患者外周血Th17和Treg细胞比率的平衡关系研究[J].中华血液学杂志,2013,34(11): 936-940.
[12] Bachanova V,Cooley S,Defor TE, et al.Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.Blood. 2014;123(25):3855-3863.
[13] Sun YX,Kong HL,Liu CF,et al.The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia.Hum Immunol.2014;75(2):113-118.
[14] Salagianni M,Lekka E,Moustaki A,et al.NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.J Immunol.2011;186(6):3327-3335.
[15] Curti A,Ruggeri L,D'Addio A,et al.Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.Blood.2011;118(12):3273-3279.
[16] Rubnitz JE,Inaba H,Ribeiro RC, et al.NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol.2010;28(6):955-959.
[17] 王远,吴昌平,卢斌峰,等.调节性T细胞在肿瘤免疫逃逸中的机制[J].中华实验外科杂志,2013,30(11):2466-2469.
[18] 王会平,沈元元,熊术道,等.老年急性髓细胞白血病患者调节性T细胞的表达及临床意义[J].中华老年医学杂志,2013,32(7): 754-756.
[19] 牟冠男,徐雯.调节性T细胞在急性髓细胞白血病中的作用[J].国际免疫学杂志,2013,36(2):106-111.
[20] Mato AR,Morgans A,Luger SM.Novel strategies for relapsed and refractory acute myeloid leukemia.Curr Opin Hematol. 2008;15(2):108-114.
[21] Fontenot JD,Gavin MA,Rudensky AY.Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells.Nat Immunol.2003;4(4):330-336.
[22] Hartigan-O'Connor DJ,Poon C,Sinclair E.Human CD4 + regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127),allowing consistent identification and sorting of live cells.J Immunol Methods.2007;319(1-2):41-52.
[23] Kanakry CG,Hess AD,Gocke CD.Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia:peripheral oligoclonal expansion of regulatory T cells.Blood.2011;(2):608-611.
[24] Prabhala RH,Neri P,Bae JE.Dysfunctional T regulatory cells in multiple myeloma.Blood.2006;(1):301-304.
[25] Zhang N,Schr(o)ppel B,Lal G.Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response.Immunity.2009; (3): 458-469.
[26] Yang W,Xu Y.Clinical significance of Treg cell frequency in acute myeloid leukemia.Int J Hematol.2013;98(5):558-562.
[27] Yang XW,Wang P,Liu JQ,et al.Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.Oncogene. 2014;33(21): 2700-2708.
[28] Iachininoto MG,Nuzzolo ER,Bonanno G,et al. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells. Molecules.2013;18(9):10132-10145.
[29] Martino M,Fedele R,Moscato T,et al.Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. Curr Cancer Drug Targets.2013;13(6):661-669.